Catalyst Pharmaceuticals (CPRX) Scheduled to Post Quarterly Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.31 per share for the quarter. Catalyst Pharmaceuticals has set its FY 2024 guidance at EPS.Parties interested in listening to the company's conference call can do so using this link.

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.45 by $0.04. The firm had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. On average, analysts expect Catalyst Pharmaceuticals to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Catalyst Pharmaceuticals Trading Up 1.0 %

NASDAQ CPRX traded up $0.15 during trading on Wednesday, hitting $15.20. 1,046,059 shares of the company's stock were exchanged, compared to its average volume of 1,451,589. The company has a market cap of $1.79 billion, a PE ratio of 24.51, a P/E/G ratio of 0.84 and a beta of 0.89. Catalyst Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $17.76. The stock's 50 day moving average price is $15.59 and its two-hundred day moving average price is $14.68.

Analysts Set New Price Targets

CPRX has been the subject of several research analyst reports. StockNews.com raised Catalyst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, March 21st. TheStreet upgraded shares of Catalyst Pharmaceuticals from a "c+" rating to a "b" rating in a research note on Tuesday, March 12th. Citigroup began coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They issued a "buy" rating and a $27.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $24.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Finally, Oppenheimer restated an "outperform" rating and set a $29.00 price target on shares of Catalyst Pharmaceuticals in a research note on Wednesday, March 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $26.43.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the transaction, the insider now directly owns 124,433 shares of the company's stock, valued at approximately $2,045,678.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.00% of the stock is currently owned by company insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.